The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials

Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment

(2017) Raymond W Lam et al.   CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE

The Effect of Vortioxetine on Health-related Quality of Life in Patients With Major Depressive Disorder

(2015) Ioana Florea et al.   CLINICAL THERAPEUTICS

Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review

(2015) Beatrice Bortolato et al.   CNS & Neurological Disorders-Drug Targets

The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder

(2015) Roger S. McIntyre et al.   CNS DRUGS

The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project

(2015) Roger S. McIntyre et al.   COMPREHENSIVE PSYCHIATRY

Treatment of cognitive dysfunction in major depressive disorder—a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine

(2015) Alan L. Pehrson et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

(2015) Joshua D Rosenblat et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

(2015) Atul R Mahableshwarkar et al.   NEUROPSYCHOPHARMACOLOGY

Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data

(2015) Connie Sanchez et al.   PHARMACOLOGY & THERAPEUTICS

The Impact of Cognitive Impairment and Comorbid Depression on Disability, Health Care Utilization, and Costs

(2015) Xiaoling Xiang et al.   PSYCHIATRIC SERVICES

Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2015) Shinji Matsunaga et al.   PLoS One

Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats

(2014) Ashley Wallace et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

(2014) Roger S. McIntyre et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS

(2013) Roger S. McIntyre et al.   DEPRESSION AND ANXIETY

P.2.e.003 Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine

(2013) M.S. Riga et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses

(2012) Stefan Leucht et al.   BRITISH JOURNAL OF PSYCHIATRY

P.2.h.002 Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition

(2012) N. Haddjeri et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Time discrimination in traumatic brain injury patients

(2012) Giovanna Mioni et al.   JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY

Patient Safety Considerations in the Rehabilitation of the Individual with Cognitive Impairment

(2012) Brad T. Tyson et al.   Physical Medicine and Rehabilitation Clinics of North America

Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: A meta-analysis and review.

(2012) Hannah R. Snyder   PSYCHOLOGICAL BULLETIN

A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder

(2011) Rico S.C. Lee et al.   JOURNAL OF AFFECTIVE DISORDERS

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Timing as a window on cognition in schizophrenia

(2011) Ryan D. Ward et al.   NEUROPHARMACOLOGY

Cognitive functioning in major depression – a summary

(2009) Åsa Hammar   Frontiers in Human Neuroscience

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management

(2009) Scott B. Patten et al.   JOURNAL OF AFFECTIVE DISORDERS

Depression and dementia

(2009) Amos D. Korczyn et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effects of lorazepam on visual perceptual abilities

(2008) S. Pompéia et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL